These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

358 related articles for article (PubMed ID: 25266910)

  • 1. Adverse reactions associated with systemic polymyxin therapy.
    Justo JA; Bosso JA
    Pharmacotherapy; 2015 Jan; 35(1):28-33. PubMed ID: 25266910
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The safety of polymyxin antibiotics.
    Kelesidis T; Falagas ME
    Expert Opin Drug Saf; 2015; 14(11):1687-701. PubMed ID: 26365594
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Are there any ways around the exposure-limiting nephrotoxicity of the polymyxins?
    Pogue JM; Ortwine JK; Kaye KS
    Int J Antimicrob Agents; 2016 Dec; 48(6):622-626. PubMed ID: 27876274
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical considerations for optimal use of the polymyxins: A focus on agent selection and dosing.
    Pogue JM; Ortwine JK; Kaye KS
    Clin Microbiol Infect; 2017 Apr; 23(4):229-233. PubMed ID: 28238870
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetics and pharmacodynamics of 'old' polymyxins: what is new?
    Bergen PJ; Landersdorfer CB; Zhang J; Zhao M; Lee HJ; Nation RL; Li J
    Diagn Microbiol Infect Dis; 2012 Nov; 74(3):213-23. PubMed ID: 22959816
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Imaging the distribution of polymyxins in the kidney.
    Yun B; Azad MA; Wang J; Nation RL; Thompson PE; Roberts KD; Velkov T; Li J
    J Antimicrob Chemother; 2015 Mar; 70(3):827-9. PubMed ID: 25377569
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vitro assessment and multicenter cohort study of comparative nephrotoxicity rates associated with colistimethate versus polymyxin B therapy.
    Phe K; Lee Y; McDaneld PM; Prasad N; Yin T; Figueroa DA; Musick WL; Cottreau JM; Hu M; Tam VH
    Antimicrob Agents Chemother; 2014 May; 58(5):2740-6. PubMed ID: 24566187
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Polymyxins - review with emphasis on nephrotoxicity].
    Mendes CA; Burdmann EA
    Rev Assoc Med Bras (1992); 2009; 55(6):752-9. PubMed ID: 20191233
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The use of intravenous and aerosolized polymyxins for the treatment of infections in critically ill patients: a review of the recent literature.
    Falagas ME; Kasiakou SK; Tsiodras S; Michalopoulos A
    Clin Med Res; 2006 Jun; 4(2):138-46. PubMed ID: 16809407
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nephrotoxicity of Polymyxins: Is There Any Difference between Colistimethate and Polymyxin B?
    Zavascki AP; Nation RL
    Antimicrob Agents Chemother; 2017 Mar; 61(3):. PubMed ID: 27993859
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Polymyxin-induced nephrotoxicity and its predictors: a systematic review and meta-analysis of studies conducted using RIFLE criteria of acute kidney injury.
    Sisay M; Hagos B; Edessa D; Tadiwos Y; Mekuria AN
    Pharmacol Res; 2021 Jan; 163():105328. PubMed ID: 33276108
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nephrotoxicity in Patients with or without Cystic Fibrosis Treated with Polymyxin B Compared to Colistin.
    Crass RL; Rutter WC; Burgess DR; Martin CA; Burgess DS
    Antimicrob Agents Chemother; 2017 Apr; 61(4):. PubMed ID: 28167560
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Polymyxins revisited.
    Landman D; Georgescu C; Martin DA; Quale J
    Clin Microbiol Rev; 2008 Jul; 21(3):449-65. PubMed ID: 18625681
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Polymyxins and their novel derivatives.
    Vaara M
    Curr Opin Microbiol; 2010 Oct; 13(5):574-81. PubMed ID: 20869908
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intravenous polymyxins: Revival with puzzle.
    Yu Y; Fei A; Wu Z; Gao C; Pan S
    Biosci Trends; 2017; 11(4):370-382. PubMed ID: 28904326
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Early prediction of polymyxin-induced nephrotoxicity with next-generation urinary kidney injury biomarkers.
    Keirstead ND; Wagoner MP; Bentley P; Blais M; Brown C; Cheatham L; Ciaccio P; Dragan Y; Ferguson D; Fikes J; Galvin M; Gupta A; Hale M; Johnson N; Luo W; McGrath F; Pietras M; Price S; Sathe AG; Sasaki JC; Snow D; Walsky RL; Kern G
    Toxicol Sci; 2014 Feb; 137(2):278-91. PubMed ID: 24189134
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Continuous renal replacement therapy-related strategies to avoid colistin toxicity: a clinically orientated review.
    Honoré PM; Jacobs R; Joannes-Boyau O; Lochy S; Boer W; De Waele E; Van Gorp V; De Regt J; Collin V; Spapen HD
    Blood Purif; 2014; 37(4):291-5. PubMed ID: 25096804
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Battle of polymyxin induced nephrotoxicity: Polymyxin B versus colistin.
    Ballı FN; Ekinci PB; Kurtaran M; Kara E; Dizman GT; Sönmezer MÇ; Hayran M; Demirkan K; Metan G
    Int J Antimicrob Agents; 2024 Feb; 63(2):107035. PubMed ID: 37979889
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Polymyxin combinations: pharmacokinetics and pharmacodynamics for rationale use.
    Bergen PJ; Bulman ZP; Saju S; Bulitta JB; Landersdorfer C; Forrest A; Li J; Nation RL; Tsuji BT
    Pharmacotherapy; 2015 Jan; 35(1):34-42. PubMed ID: 25630411
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Toxicity after prolonged (more than four weeks) administration of intravenous colistin.
    Falagas ME; Rizos M; Bliziotis IA; Rellos K; Kasiakou SK; Michalopoulos A
    BMC Infect Dis; 2005 Jan; 5():1. PubMed ID: 15642116
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.